Table 3 Estimated haplotype frequencies in controls, patients with sporadic prostate cancer (SPC) and patients with advanced prostate cancer
From: Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk
Haplotype | Controls | Cases | SPC | Advanced PC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
rs878972 | rs315934 | rs3087263 | rs315951 | % | % | Score a | P b | % | Score a | P b | % | Score a | P b |
A | T | G | C | 33.5 | 38.7 | 2.60 | 0.009 | 39.3 | 2.85 | 0.006 | 40.0 | 2.67 | 0.009 |
A | T | G | G | 17.6 | 15.5 | −1.01 | 0.301 | 15.0 | −1.24 | 0.215 | 15.0 | −1.15 | 0.246 |
C | T | G | C | 17.5 | 15.3 | −1.16 | 0.234 | 15.2 | −1.22 | 0.208 | 14.1 | −1.78 | 0.080 |
A | C | G | G | 14.3 | 13.6 | −0.58 | 0.560 | 14.0 | −0.41 | 0.667 | 14.9 | 0.45 | 0.655 |
C | T | A | C | 8.4 | 7.7 | −0.80 | 0.428 | 7.9 | −0.64 | 0.513 | 8.4 | −0.20 | 0.839 |
A | C | G | C | 5.8 | 5.4 | −0.38 | 0.713 | 4.9 | −0.89 | 0.367 | 4.8 | −0.86 | 0.401 |
C | T | G | G | 1.8 | 2.7 | 0.97 | 0.337 | 2.9 | 1.06 | 0.274 | 2.4 | 0.17 | 0.872 |
C | T | A | G | 0.6 | 0.7 | 0.33 | 0.737 | 0 | 0 | ||||
Overall | 0.116 | 0.052 | 0.024 | ||||||||||
